Trials List

Indiana University Health Arnett Cancer Services participates in a network of established, highly advanced research affiliations that provide the latest treatment options to people with cancer.

Clinical trials are vital in the fight against cancer because they answer important questions about which drug therapy or combination of therapies is the most effective for a particular type of cancer. Your oncologist can explain more about clinical trials and if participation is appropriate for your situation.

Participating in trials offered by:

• National Surgical Adjuvant Breast and Bowel Project (NSABP) of the National Cancer Institute
• Eastern Cooperative Oncology Group (ECOG)
• Hoosier Oncology Group (HOG), supported by the National Cancer Institute
• Pharmaceuticals

For more information about IU Health Arnett oncology/hematology clinical trials, or if you would like to participate, please contact:

Janice Welty, RN, OCN, CCRP
Oncology Clinical Trials Nurse Coordinator
765.448.7536
Fax: 765.448.7626
weltyj@iuhealth.org

Currently participating in trials for the treatment of:

Bladder Cancer

• SEE GENITOURINARY

Brain Cancer

• NO STUDIES AT THIS TIME

Breast Cancer

• Endocrine Therapy in Combination with anti-VEGF Therapy: A Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Endocrine Therapy Alone or Endocrine Therapy Plus Bevacizumab (NSC 704865; IND 7921) For Women with Hormone Receptor-Positive Advanced Breast Cancer.
• A Phase III Clinical Trial Comparing the Combination of TC Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer. (T=Docetaxel, C=Cyclophosphamide, A=Doxorubicin)
• A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer.

Colorectal Cancer

• A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (c225) or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum
• Phase II Study of Treatment Selection Based Upon Tumor Thymidylate Synthase Expression in Previously Untreated Patients with Metastatic Colorectal Cancer.
• A Phase III Trial of 6 Versus 12 Treatments of Adjuvant FOLFOX Plus Celecoxib Or Placebo For Patients With Resected Stage III Colon Cancer.
• A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy.
• Phase II Study of Second Line Therapy with Irinotecan and Cetuximab with or without RAD001, an Oral MTOR Inhibitor for Patients with Metastatic Colorectal Cancer.

Esophageal Cancer

• NO STUDIES AT THIS TIME

Gastric Cancer

• NO STUDIES AT THIS TIME

Genitourinary Cancer

• A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitabine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma (renal pelvis, ureter, bladder, prostate, or urethra)
• A Biological Sample Collection Protocol of Patients with and without Metastatic Solid Organ Malignancies. (Pancreatic & Bladder Cancers) 

Head and Neck Cancer

• NO STUDIES AT THIS TIME

Leukemia

• NO STUDIES AT THIS TIME

Lung Cancer

• A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>4cm) -IIIA Non-Small Cell Lung Cancer (NSCLC)
• A Randomized Double Blind Phase II Trial of Cisplatin plus Etoposide with/without Concurrent ZD6474 in Patients with Previously Untreated Extensive Stage Small Cell Lung Cancer.
• Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed Following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-Squamous NSCLC.
• The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blinded Placebo Controlled Study.

Lymphoma

• An Open-Label Study of Bendamustine Hydrochloride in Combination with Rituximab in the Treatment of Patients with Relapsed/Refractory Mantle Cell Lymphoma.
• Phase II Study of Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma
• A 3-Arm Randomized Phase II Trial of Bendamustine-Rituximab (BR) Followed by Rituximab vs Bortezomib-BR (BVR) Followed by Rituximab vs BR Followed by Lenalidomide/Rituximab in High Risk Follicular Lymphoma.

Myelodysplastic Syndrome

• Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risk MDS and Symptomatic Anemia.

Multiple Myeloma  

• An Intergroup Phase III Randomized Controlled Trial Comparing Melphalan, Prednisone and Thalidomide Versus Melphalan, Prednisone and Lenalidomide in Newly Diagnosed Myeloma Patients Who Are Not Candidates for High-Dose Therapy.
• A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer.
• Randomized Phase III Trial of Lenalidomide Versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma

Ovarian Cancer

• NO STUDIES AT THIS TIME

Pancreas

• A Biological Sample Collection Protocol of Patients with and without Metastatic Solid Organ Malignancies. (Pancreatic and Bladder Cancers)

Prostate Cancer

• A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer.
• SEE GENITOURINARY

Rectal Cancer

• A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab, or Cetuximab (c225) or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum

Renal Cancer

• SEE GENITOURINARY

Miscellaneous

• A Biological Sample Collection Protocol of Patients with and without Metastatic Solid Organ Malignancies. (Healthy Patients and Metastatic Lung, Pancreatic & Bladder Cancers) 
• A Randomized, Phase III Study of Standard Dosing versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer. (Prostate, Multiple Myeloma, Breast)
• The Use of Glutathione (GSH) for Prevention of Paclitaxel/Carboplatin (TAXOL/CBDCA) Induced Peripheral Neuropathy: A Phase III Randomized, Double-Blind Placebo Controlled Study.

Prevention Trials

• NO STUDIES AT THIS TIME